Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

3D models of human ERα and ERβ complexed with coumestrol.
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.
ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients
Connective Tissue and its Growth Factor, CTGF, Distinguish the Morphometric and Molecular Remodeling of the Bladder in a Model of Neurogenic Bladder.
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark.
Sanofi sees US FDA ruling for MS drug Lemtrada in Q4
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
UVB light attenuates the systemic immune response in CNS autoimmunity.
The little compound that could: how phenytoin changed drug discovery and development.
Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Complementary and alternative medicine in multiple sclerosis.
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Recurrence of disease activity after repeated Natalizumab withdrawals.
Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene.
Influence of cigarette smoking on white matter in patients with clinically isolated syndrome as detected by diffusion tensor imaging.
The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome.
How Natalizumab Binds and Antagonizes α4 Integrins.
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
High dose naltrexone for dyskinesias induced by levodopa.
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.

Pages